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Abstract
Background: Drug resistance contributes to the global malaria burden. Plasmodium falciparum dihydrofolate
reductase (dhfr) and dihydropteroate synthase (dhps) polymorphisms confer resistance to sulphadoxine-
pyrimethamine (SP).
Methods: The study assessed the frequency of SP resistance-conferring polymorphisms in Plasmodium falciparum-
positive samples from two clinical studies in Lambaréné. Their role on treatment responses and transmission
potential was studied in an efficacy open-label clinical trial with a 28-day follow-up in 29 children under five with
uncomplicated malaria.
Results: SP was well tolerated by all subjects in vivo. Three subjects were excluded from per-protocol analysis.
PCR-corrected, 12/26 (46%) achieved an adequate clinical and parasitological response, 13/26 (50%) were late
parasitological failures, while 1/26 (4%) had an early treatment failure, resulting in early trial discontinuation. Of 106
isolates, 98 (92%) carried the triple mutant dhfr haplotype. Three point mutations were found in dhps in a variety of
haplotypic configurations. The 437G + 540E double mutant allele was found for the first time in Gabon.
Conclusions: There is a high prevalence of dhfr triple mutant with some dhps point mutations in Gabon, in line
with treatment failures observed, and molecular markers of SP resistance should be closely monitored.
Trial Registration: ClinicalTrials.gov: NCT00453856
Background
Plasmodium falciparum malaria is a major cause of
morbidity and mortality amongst children in sub-
Saharan Africa; killing an estimated 1 million children
below five years of age annually [1].
Chloroquine and sulphadoxine-pyrimethamine (SP)
were, until fairly recently, the mainstays of malaria treat-
ment in Africa. Resistance to chloroquine is now wide-
spread, while resistance to SP increases. When used as
first line treatment for malaria, SP exerts a strong
selection pressure on parasite populations, thus increas-
ing the frequency of resistance mutations in the dihy-
drofolate reductase (dhfr) gene which codes for the
enzyme DHFR (the target of pyrimethamine) [2,3] and
the dihydropteroate synthase (dhps) gene which codes
for the enzyme DHPS (the target of sulphadoxine) [4,5]
in the parasite reservoir [6]. These mutations are known
to confer resistance to the component drugs of SP in P.
falciparum, and this rise in resistance has been well
documented in studies in vivo throughout the African
continent [7-11]. Consequently, there is now a general
move towards artemisinin-based combination therapy as
first line anti-malarial treatment of uncomplicated falci-
parum malaria [12]. As elsewhere, in the Lambaréné
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area in the Moyen Ogoué Province, Gabon, artemisinin-
based combination therapy is increasingly frequently
prescribed and administered (Profanter et al., submitted
for publication). However, the use of SP for curative
treatment in Gabon is still common because it is afford-
able on household level. SP is also recommended for
use as intermittent preventive treatment of malaria in
pregnancy (IPTp) [13] whilst intermittent preventive
treatment in infants (IPTi) with SP has been evaluated
in detail [14] and has recently been adopted by the
World Health Organization as an additional malaria
control tool [15]. Given these facts, monitoring of SP
resistance remains an important task.
Different combinations of point mutations in the para-
site’s dhfr and dhps genes confer varying levels of drug
tolerance. A dhfr codon 108 exchange (Ser-108 to Asn-
108) confers mild pyrimethamine tolerance. The addi-
tional presence of Ile-51 and Arg-59 confers pro-
nounced resistance to pyrimethamine and predicts SP
treatment failure in some areas. Similarly, for dhps,
mutant Gly-437 is associated with some sulfonamide
resistance while additional changes Glu-540, Gly-581,
and Ser-613 appear to increase its degree [16]. A com-
mon mutation Ala-436 is generally considered an alter-
native wild type polymorphism [17]. The combination of
the dhfr triple mutant together with a dhps Gly-437 +
Glu-540 double mutant has been shown to predict SP
treatment failure in East African settings [18,19] but this
genotype is rare in West Africa.
This paper reports the prevalence of dhfr and dhps
point mutations in P. falciparum isolates collected from
children with malaria attacks in Lambaréné from 2005
to 2007, and the associations of these point mutations
with SP treatment outcome.
Methods
Study area and samples
Blood samples positive with P. falciparum were col-
lected from patients and asymptomatic individuals dur-
ing two separate studies from 2005 to 2007, initiated by
the IPTi consortium [14] and carried out at the Medical
Research Unit of the Albert Schweitzer Hospital in Lam-
baréné, Gabon. In this study area of 30,000 inhabitants,
malaria transmission is perennial, with little seasonal
variation [20,21].
One study was an IPTi trial (ClinicalTrials.gov identi-
fier: NCT00167843) reported elsewhere [21,22] and
included into a meta-analysis of IPTi-SP trials across
Africa [14].
The second study as reported here was an in vivo
therapeutic efficacy trial of SP in children aged 6-59
months with uncomplicated falciparum malaria (Clin-
icalTrials.gov identifier: NCT00453856). Both studies
were approved by the ethics committee of the
International Foundation of the Albert Schweitzer
Hospital.
Both studies included children from Lambaréné and
its vicinity. Informed consent was obtained from parents
or legal representative for each subject prior to enrol-
ment. Children with acute febrile disease were physically
examined; a thick blood film was screened for malaria
parasites and a finger-prick blood sample for filter paper
blood spotting (FTA Classic Card, Whatman Inc., San-
ford, ME, USA) was obtained. The filter paper blood
spots were air dried and stored at 4°C in individual plas-
tic bags with desiccant and genotyping analysis later
performed at the London School of Hygiene and Tropi-
cal Medicine (London, UK).
SP treatment in vivo study-specific procedures
The target sample size of 139 children was determined
from a therapeutic efficacy between 70 and 95%, with a
precision of 7.5% allowing for a 20% drop-out. The
study end points were adequate clinical and parasitologi-
cal response, late clinical failure, late parasitological fail-
ure and early treatment failure as defined by the World
Health Organization [23]. These were calculated in the
per-protocol population, while safety and tolerance were
evaluated in the intention-to-treat population, all chil-
dren who received single-dose SP.
Study physicians examined all eligible children at
enrolment, recording blood pressure, pulse and axillary
temperature. Laboratory data recorded were parasite
density of asexual and sexual forms of malaria, haemo-
globin, haematocrit, white blood cell count, thrombocyte
count (ABX Pentra 60®, ABX Diagnostics, Montpellier,
France), creatinine and alanine- aminotransferase (ABX
Mira Plus®, ABX Diagnostics).
A single dose of SP (25 mg/kg and 1.25 mg/kg; Man-
eesh Pharmaceuticals PVT Ltd, Govandi Mumbai, India)
was crushed and mixed with glucose solution and admi-
nistered orally by a study clinician. A patient was with-
drawn from the trial if a re-dose was vomited and the
outcome was early treatment failure, late clinical failure
or late parasitological failure according to WHO defini-
tions [23]. These patients were subsequently treated
with oral artemether-lumefantrine (COARTEM®, Novar-
tis Pharma Ltd Beijing for Novartis Pharma AG, Basle
Switzerland) or hospitalized, if oral treatment was not
tolerated. Scheduled follow up visits of all study subjects
were on days 1, 2, 3, 7, 14, 21 and 28 after oral adminis-
tration of SP (day 0).
DNA extraction and PCR amplification of dhfr and dhps
genes
DNA was extracted from bloodspots dried on filter
papers by soaking overnight in 1 mL of 0.5% saponin-1x
phosphate buffered saline. The segment was then
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washed twice in 1 mL of PBS and boiled for 8 min in
100 μL PCR quality water with 50 μL 20% Chelex sus-
pension (pH 9.5).
Dhfr and dhps were PCR amplified using a nested
PCR. The outer and nested dhfr/dhps PCR conditions,
including primer sequences and reaction parameters,
were as previously described [24]. The nested PCR pro-
ducts were confirmed by electrophoresis on a 1% agar-
ose gel along with a set of controls.
Molecular genotyping of point mutations using SSOP
Point mutations at codons 51, 59, 108 and 164 of the
dhfr gene and codons 436, 437, 540, 581, and 613 of the
dhps gene were genotyped using the Sequence Specific
Oligonucleotide Probes (SSOP), a dot-blot methodology
previously described by Pearce and colleagues [24]. The
probed blots were visualized through alkaline phospha-
tase-catalyzed breakdown of the fluorogenic substrate
(ECF) (GE Healthcare, Buckinghamshire, UK) and the
chemifluorescent signal scanned on a TYPHOON Trio®
Phosphoimager (GE Healthcare, Buckinghamshire, UK).
The stringency and specificity of the hybridization
process was confirmed by inspection of a series of four
controls of known single genotype variant sequence. All
blots with non-specifically bound probes were stripped
and re-probed. A sequence variant was considered to be
present in the PCR product when the intensity of signal
was higher than that of the background. The presence,
absence, and relative abundance of hybridization signal
were recorded for every probe at each locus. Blood sam-
ples were categorized as having a single, a majority plus
a minority, or a mixture of sequences at every locus. A
sample was considered to have a single haplotype when
only one sequence variant was found at each locus.
Majority and mixed genotype infections were differen-
tiated according to the relative intensity of signal.
Molecular treatment outcome measures
Each P. falciparum infection was characterized on the
basis of the MSP-2 polymorphism [25]. Allele-specific
PCR to amplify FC27 or IC1/3D7 fragments was per-
formed on paired pre- and post-treatment bloodspot
samples. Cases in which pre- and post-treatment geno-
types were identical were considered as recrudescence, i.
e. failures; cases in which pre- and post-treatment geno-
types were different were considered as re-infections;
mixed genotypes were classified as failures. Parasite
clearance time was defined as the time from starting SP
treatment until parasites were undetectable in two con-
secutive peripheral blood films at least 24 hrs apart. An
experienced laboratory technician measured asexual
parasitaemia per μL according to the Lambaréné
method [26]. The presence of single or multiple dhfr or
dhps mutations from samples collected prior to
treatment with SP were examined for their association
with patients’ treatment outcome. Each isolate was
coded based on the presence or absence of a resistance
associated allele. For example, infections with mixed
wild-type/mutant alleles were treated as mutant.
Transmission potential was evaluated by measuring
gametocytaemia on enrolment and at scheduled visits
following the same technique used for asexual
parasitaemia.
Statistical methods
The study analysis consisted on calculating the propor-
tion of malaria infections with mutations of interest pre-
sent in samples from the IPTi plus those present at the
time of enrolment in the SP in vivo study and estimated
95 percent binomial confidence intervals for prevalence
of mutations in the study area.
For the SP treatment in vivo study, data were entered
into an electronic database and validated by complete
manual review. Statistical analysis was performed using
Stata (Stat Corp., College Station, TX, USA) statistical
software. Fever clearance time was calculated as the
time from the start of treatment to the first of two con-
secutive axillary temperature measurements that
recorded below 37.5°C and parasite elimination time as
the time from the start of treatment to that of two con-
secutive negative blood smears.
Results
SP in vivo treatment response
Of the 29 patients who received a standard oral dose of
SP in the study assessing the in vivo efficacy of SP, 18
(62.1%) completed the 28-day active follow-up, before
the trial was stopped for safety concerns. The targeted
sample size was not attained because after 29 subjects
were enrolled, a decision to stop the trial was taken by
the investigators because of concerns about the early
treatment failure. Figure 1 provides the study flow, and
Table 1 provides baseline characteristics of patients and
details on day 28 cure rates. Clinically, 14 subjects
developed treatment failure, with one early and 13 late
treatment failures. Three patients were excluded from
per protocol analysis, because of mixed infections with
other Plasmodium species (n = 2), and parents withdra-
wal of a consent for one child at the follow-up visit day
28. Matched sample pairs collected before and after
treatment from 26 subjects were analyzed at the msp-2
locus. Overall, 12 subjects (46%) had an adequate clini-
cal and parasitological response, including two subjects
with parasites on day 28 post-treatment which were new
infections, while 14 (54%) carrying parasites in the post-
treatment sample probably failed SP treatment.
Mean fever clearance time was 22 hours, parasite
elimination time was 61 hours and the gametocytes
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carriage rate was 85%. On enrolment (D0) the mean
haemoglobin was 9.4 g/dL; 45% of the subjects (13/29)
had a haemoglobin less than 9.0 g/dL - a mean change
in hemoglobin between D0 to D28 of 1.5 g/dL (CI; 1 -
2.1, p < 0.0001).
Oral SP was well tolerated by all 29 subjects. There
were 26 adverse events reported during the course of
this study; worm infestation (n = 9), respiratory infec-
tion (n = 8), anaemia (n = 4), skin infections (n = 4)
and diarrhoea (n = 1). There was no serious adverse
event observed during this trial except the hospitaliza-
tion (per protocol) of one patient who had an early
treatment failure.
Prevalence of dhfr and dhps point mutations
Of the total 155 falciparum-positive samples collected in
Lambaréné from 2005 to 2007 and sent for analysis, 106
yielded PCR products for dhfr and 121 for dhps. Among
these, 5% were infections with mixed strains at dhfr and
26% were mixed at dhps. The high number of mixed
infections was a reflection of the high level of transmis-
sion in the area.
Three point mutations were found in dhfr; 51I, 59R
and 108N, while 164L and 108Thr were absent. A high
proportion of infections (98/106; 92%) were found to
have the triple mutant dhfr 51I-59R-108N, while the
sensitive wild-type was absent. The single mutant 59R
(NRS) was present only in one sample (1%) (Table 2).
Three point mutations were found in dhps; 436A, 437G
and 540E, while 581G and 613T were absent. The pre-
valence of dhps single mutant haplotypes containing
436A alone, 18/121 (15%) or 437G alone, 60/121 (50%)
were higher than double mutant haplotypes dhps 436A
+ 437G, 6/121 (5%) and 437G + 540E, 4/121 (3%)
(Table 2). The dhps wildtype haplotype (SAK) was
found in 2/121 (2%) of infections.
The combined dhfr and dhps haplotypes were avail-
able for 102 samples. The triple mutant dhfr 51I-59R-
108N was found in combination with dhps 437G in 44
isolates (43%). Of these, just 4 (4%) carried the ‘quintu-
ple’ genotype (dhfr 51I-59R-108N + dhps 437G + 540E),
which is predictive of SP treatment failure. The com-
bined sensitive alleles for dhfr and dhps were not
observed in any of the isolates. Therefore, dhfr/dhps
combined individual infections according to the number
of mutations at dhfr and dhps codons were categorized
as M3, M4, and M5 (Table 3).
Of the 29 pre-treatment isolates, the analysis of the
dhfr product at each of the codons found with point
mutations - 51, 59 and 108 - showed that most of the
infections were from mutant strains, as depicted in
Table 4. Interestingly, all the positive samples at post-
treatment carried the point mutations 51I (8/26), 59R
(12/26), and 108N (10/26) (Table 4).
Regarding dhps, an analysis specific to the combined
codons 436/437 showed prior to treatment that the 436/
437SG was the most frequent haplotype either in mono-
or mixed infections and also post-treatment (Table 5).
Enrolment n=29 
29 subjects took sulphadoxine – pyrimethamine orally 
3 subjects excluded from per-protocol analysis 
1 withdrawal of consent 
2 mixed infection 
26 subjects for per - protocol analysis 
12 out of 26 subjects were cured (PCR-adjusted) 
Figure 1 Study flow chart.
Table 1 Baseline Characteristics and results of the SP
efficacy study
Number of patients 29
Age, mean (SD), months 34.8 (16.6)
Sex ratio (male/female) 1.9 (19/10)
Weight, mean (SD), kg 13.0 (2.5)
Axillary temperature at admission, mean (SD), °C 37.1 (0.95)
Parasitaemia at admission, median (quartiles) 18,718 (2,800-
33,300)
Day 28 PCR adjusted cure in PP analysis, n (%)
Day 28 unadjusted cure in PP analysis, n (%)
12/26 (46) 10/26
(38.5)
Early treatment failures, n (%) 1 (4)
Late parasitological failures, n (%) 13 (50)
Parasite clearance time, mean (95%CI), hours 61 (45-76)
Fever clearance time, mean (95%CI), hours 22 (14-30)
Gametocyte carrier rate at admission, n (%) 2 (6)
Gametocytes carrier rate during follow-up, n (%) 22 (85)
SD: Standard Deviation, PCR: Polymerase Chain Reaction, CI: Confidence
Interval, n: number of patients.
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Mutations and parasite clearance time
The cumulative parasite clearance time distribution for
the 29 study subjects was as follows: 17% (5/29), 57%
(13/23) and 60% (6/10) cleared parasites by days 1, 2
and 3, respectively. Subjects with a parasite clearance
time longer than 3 days (n = 4), included two children
with treatment failure and two children with adequate
responses. Two subjects (8%) did not clear parasites
until the visit after day 7 of treatment and were consid-
ered as late parasitological failure. The proportion of
subjects who by Day 3 after treatment have not cleared
parasites (~40%) was relatively high and certainly asso-
ciated with the mere presence of the dhfr triple mutant,
as the risk estimate did not increase when comparing
dhfr triple mutant alone and combined with dhps single
and double mutants, odds ratio (OR) (95% CI) for para-
site clearance time longer than 3 days of 1.9 (0.1 - 52.8)
and 1.3 (0.03 - 53.6), respectively.
Mutations and treatment outcome
Drug and iron plasma concentrations, or biostatistics
information like age and sex were not taken into
account, as any influence on treatment response has not
been reported previously [27]. The very small number of
patients does not allow for strong conclusions; however,
the high rates of SP treatment failure in this study
obviously correlate with the high rates of dhfr triple
mutant isolates, and with the emergence of dhps 540E
under treatment. The addition of dhps mutations had
not increased this risk, as OR (95% CI) for dhfr/dhps
combined were 6.3 (0.2 - 180.4) and 3.0 (0.1 - 115.4),
respectively, for M4 and M5.
Peak gametocytaemia occurred 7 days after treatment,
when 17 (50%) subjects had detectable gametocytes, up
from 2 (6%) at baseline. Dhps haplotypes were not asso-
ciated with gametocyte prevalence or density at any
time.
Discussion
These findings show a high prevalence (98/106; 92%) of
parasites with triple mutant 51I-59R-108N dhfr haplo-
type in the study area. Previous studies in Gabon point
to an increase in the prevalence of resistant dhfr in
recent years. Fifty percent prevalence of 108N was
found in Lambaréné in 1996 [28], and 90% was reported
from Franceville in 1998 [29]. A later study conducted
in Bakoumba in 2000 [30] reported a prevalence rate of
72% of triple-mutant dhfr. Consistent with those earlier
Table 2 Prevalence of dhfr and dhps haplotypes in
isolates from Plasmodium falciparum positive patients
from Lambaréné, Gabon, 2005-2007
dhfr N = 106 %
Single mutant 1 1
Double mutant 2 2
Triple mutant 98 92
MIX 5 5
dhps N = 121 %
Sensitive 2 2
Single mutant (436A only) 18 15
Single mutant (437G only) 60 50
Double mutant (436A + 437G) 6 5
Double mutant (437G + 540E) 4 3
MIX 31 26
MIX: infections with mixed strains
Table 3 Combined dhfr and dhps haplotypes

































dhfr_51I-59R-108N + dhps_MIX MIX 24 24
dhfr_51N-59R-108S + dhps_MIX MIX 1 1
dhfr_MIX + dhps_436S-437G-540K MIX 1 1
dhfr_MIX + dhps_MIX MIX 4 4
Table 4 Prevalence of dhfr gene mutations at enrolment
and at day of failure in children included in the in vivo
study
DHFR
Pre-treatment N = 29
Codon 51 59 108 164
Sensitive N C S I
1 (3%) 2 (7%) 0 28 (97%)
Mutant I R N L
23 (79%) 26 (90%) 26 (90%) 0
No PCR product 5 1 3 1
Post-treatment N = 26
Codon 51 59 108 164
Sensitive N C S I
0 0 0 12 (46%)
Mutant I R N L
8 (31%) 12 (46%) 10 (38%) 0
No PCR product 18 14 16 14
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studies no mutation at dhfr codons 164 (Leu-164) was
found in the study reported here; neither Thr-108,
which is associated with cycloguanil resistance [28-30].
In the in vivo study assessing the SP efficacy, the
results show an unacceptable PCR-corrected failure rate
of 54%. In earlier studies assessing the in vivo efficacy of
SP in Gabon from 1995 - 2006 cure rates were higher,
ranging from 69% to 95% [10,27-34]. Similarly, in vitro
studies also showed an increasing rate of resistance,
from 30% in 1992 [35] to 75% in 2000 [30], which
seems to correlate with the increase of the dhfr-resistant
genotypes as well. At the dhps codons, the most fre-
quent haplotypes were single mutant dhps haplotypes
436A and 437G (Table 2). The prevalence of 437G over-
all was 58% (Table 2), which compares to 28% (10 of 36)
in Lambaréné in 1996 [28], 37% (14 of 38) in Franceville
in 1998, [29] and 63% (70 of 110) in Bakoumba in 2000
[30].
Because the clinical trial had to be terminated prema-
turely on the grounds of unexpected high therapeutic
failure rates, it was underpowered to show a statistical
correlation between the presence of dhfr or dhps muta-
tion and SP efficacy. The finding of high prevalence of
dhfr triple mutant and dhps 437G mutations, coinciden-
tal with high rates of failures point to deterioration of
SP treatment efficacy in Gabon. These findings suggest
that in Gabon, the prevalence of the dhfr triple mutation
and dhps 437G and 540E could be used as tool to
screen for and monitor SP resistance. Although factors
associated with treatment success such as drug absorp-
tion, immunity and folate levels [36,37] as well as para-
site density [38] would increase the precision predicting
resistance; in practice, molecular markers need to be
simple and easy to apply. Another important factor
associated with treatment success is drug quality,
whether or not good manufacturing practice standards
have been followed. However, treatment efficacy assess-
ment and molecular markers appear to be of limited use
when it comes to assessing the usefulness and appropri-
ateness of IPT-SP. Indeed, when used for malaria pre-
vention, SP appears in some settings to function despite
high rates of resistant haplotypes and reduced efficacy
in treatment of symptomatic malaria.
Gametocyte carriage is known to be elevated following
SP failure [39], dhfr mutants were associated with
increased gametocytaemia despite a high therapeutic
efficacy of SP in Colombia [40]. Gametocyte carriage
one week following treatment was increased in our
study, contemporaneous with the high frequency of dhfr
triple mutant parasites. These findings lead to the
assumption that dhfr mutations might influence gameto-
cyte prevalence.
Conclusions
These results show the high prevalence of dhfr triple
mutant and some dhps point mutations in Gabon,
which could explain the longer parasite clearance time,
increased SP treatment failure rates and the high rate of
gametocyte carriers after SP treatment.
This paper supports the appropriateness of discoura-
ging the use of SP for the treatment of malaria in sub-
Saharan Africa as reflected in current guidelines with a
shift towards artemisinin-based combination therapy;
hence, SP drug pressure is likely to decrease soon,
which may limit the spread of SP-resistant parasites and
therefore permit SP to continue to be used for IPT in
pregnant women and infants whenever applicable.
What are the implications for IPTi-SP as a possible
tool for malaria control in the Gabonese setting? The
original IPTi trial in Gabon [21] yielded reductions in
malaria episodes and anemia in the same order of mag-
nitude as others [14], yet did not reach statistical signifi-
cance due to a variety of reasons, including a
pronounced Healthy Cohort Effect. The current World
Health Organization guideline on IPTi with SP in chil-
dren [15] recommends a ≥ 50% cut-off of dhps 540E as
benchmark for discouraging IPTi-SP use. In the particu-
lar setting of the study, the results show for the first
time isolates carrying this polymorphism in a small sam-
ple size, and in correlation with significant treatment
failure. In summary, molecular markers of SP resistance
Table 5 Prevalence of dhps gene mutations at enrolment




436/437 SA 436/437 SG 436/437 AA 436/437 AG N = 29 %
0 1 0 0 11 38
1 0 0 0 1 3
1 1 0 0 1 3
0 1 0 1 2 7
0 0 1 0 2 7
0 1 1 0 7 24
1 0 1 0 1 3
0 1 1 1 4 14
Post-treatment
436/437 SA 436/437 SG 436/437 AA 436/437 AG N = 26 %
0 0 0 0 11 42
0 1 0 0 10 38
1 1 0 0 1 4
0 0 0 1 1 4
0 0 1 0 2 8
0 1 1 0 1 4
SA: sensitive, wild-type; SG: single mutant 437G; AA: single mutant 436A;
double mutant 436A + 437G
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and particularly dhfr triple mutants and dhps 540E need
to be closely monitored in Gabon. Although the dhps
540E benchmark of 50% has not been formally reached
in this study, Gabon is at present most likely to be con-
sidered as one of those countries falling below the
threshold in the decision-making for IPTi-SP
introduction.
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